A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms RADIANCE
- Sponsors Nichi-Iko Pharmaceutical
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 03 Mar 2017 Status changed from not yet recruiting to recruiting.